EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Non-coding RNAs in cancer: multi-omics insights, liquid biopsy advances, drug resistance mechanisms, and the road to clinical translation

Şeyma Tutar, Vida Rezayifar, Hamida Abakar Mohamed Elhaj, Merve Tutar, Cennet Ataman, Lütfi Tutar

Frontiers in Oncology · 20.08.2026 · 16

DOI: 10.3389/fonc.2026.1924660 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 20.08.2026. Verfasst von Şeyma Tutar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biochemistry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For most of the twentieth century, the transcriptional output of the human genome was thought to be biologically inert—a characterization that has been proven wrong in almost every important respect. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar RNAs (snoRNAs) and PIWI-interacting RNAs (piRNAs) are now thought of as vital regulators of gene expression in all the stages of cancer pathogenesis, including the initial epigenetic changes, metastatic spread and the development of therapeutic resistance. This review highlights four areas where the clinical potential of ncRNAs is most promising: reconstruction of ncRNA regulatory networks by multi-omics integration; circulating ncRNAs as minimally invasive cancer biomarkers; causal roles of ncRNAs in drug resistance through epithelial-mesenchymal plasticity, metabolic reprogramming, and stromal communication; and translation of ncRNA targeting strategies to clinical trials. We will need to invest equally in mechanistic rigor and translational infrastructure to move forward.

Schlagwörter

Stichwörter der Autor:innen

antisense oligonucleotidesclinical trialsdrug resistanceimmune modulationliquid biopsynon-coding RNAspersonalized medicinetherapeutic target

Autor:innen und Institutionen

  • Division of Biochemistry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
  • Division of Clinical Biochemistry, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
  • Department of Biology, Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany.
  • Molecular Biology Laboratory (Food Analysis Department), Lifeprint GmbH, Illertissen, Germany.
  • Departmant of Molecular Biology and Genetics, Faculty of Science and Letters, Kırşehir Ahi Evran University, Kırşehir, Türkiye.

Zitieren

APA

Tutar, Ş., Rezayifar, V., Elhaj, H. A. M., Tutar, M., Ataman, C., & Tutar, L. (2026). Non-coding RNAs in cancer: multi-omics insights, liquid biopsy advances, drug resistance mechanisms, and the road to clinical translation. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1924660

Vancouver

Tutar Ş, Rezayifar V, Elhaj HAM, Tutar M, Ataman C, Tutar L. Non-coding RNAs in cancer: multi-omics insights, liquid biopsy advances, drug resistance mechanisms, and the road to clinical translation. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1924660

BibTeX
@article{Tutar2026,
  author = {Tutar, Şeyma and Rezayifar, Vida and Elhaj, Hamida Abakar Mohamed and Tutar, Merve and Ataman, Cennet and Tutar, Lütfi},
  title = {Non-coding RNAs in cancer: multi-omics insights, liquid biopsy advances, drug resistance mechanisms, and the road to clinical translation},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1924660}
}
Kostenlos starten →